

bevacizumab (Avastin)

(No. 459/08)

Roche Pharmaceuticals

Statement of Advice

08 February 2008

ADVICE: in the absence of a submission from the holder of the marketing authorisation.

bevacizumab (Avastin) is not recommended for use within NHSScotland in combination with interferon alfa-2a for the first line treatment of patients with advanced and/or metastatic renal cell cancer.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman,
Scottish Medicines Consortium**